Tag Archives: Vidaza

November, 2015

  • 2 November

    EC Approves Celgene’s Vidaza for Treatment of AML

    BOUDRY, Switzerland–(BUSINESS WIRE)– Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that theEuropean Commission (EC) has approved VIDAZA® (azacitidine for injection) for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia (AML) who are not eligible for haematopoietic stem cell …